In contrast, the researchers found DAS28 ESR and HAQ-DI could predict response only in patients with high disease activity at baseline and/or those previously treated by a biological disease-modifying anti-rheumatic drug. Both disease severity at baseline and treatment history affected the ability of these two measures to predict long-term treatment failure. The authors conclude CDAI can best be used to identify certolizumab treatment failures at three months and prevent patients from being unnecessarily exposed to ineffective therapy.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Saraux A, Flipo RM, Fagnani F, et al. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. RMD Open. 2020 Jan;6(1). pii: e000991.